Representative(s):

Johns Assalone 
TAGRISSO® (osimertinib) Representative 
john.assalone@astrazeneca.com 

Frank Schuh
IMFINZI® (durvalumab) Representative
frank.schuh@astrazeneca.com 

Peggy Barbola
CALQUENCE® (acalabrutinib) Representative
peggy.barbola@astrazeneca.com 

Hayley Larkin
LYNPARZA® (olaparib) Representative 
Hayley.Larkin@astrazeneca.com 

Kathy Limoni
LYNPARZA® (olaparib) Representative 
Kathryn.Limoni@astrazeneca.com

Kim Brier 
LYNPARZA® (olaparib) Representative 
kim.brier@astrazeneca.com 

Barry Eberhardt 
ADC Franchise Representative 
barry.eberhardt@astrazeneca.com 

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.

Websites:

• Company Website
  • www.astrazeneca-us.com
• IMFINZI® (durvalumab) US HCP Website
  • www.imfinzihcp.com 
• TAGRISSO® (osimertinib) US HCP Website
  • www.tagrissohcp.com   
• CALQUENCE® (acalabrutinib) US HCP Website
  • www.calquencehcp.com 
• LYNPARZA® (olaparib) US HCP Website
  • www.lynparzahcp.com 
• ENHERTU® (fam-trastuzumab deruxtecan-nxki) US HCP Website - Click to see complete Prescribing Information, including Boxed WARNINGS
  • https://www.enhertuhcp.com/en/

Virtual Exhibit Hall

March 6th,  12:00 - 1:00 p.m.

Click here to join the virtual exhibit

Meeting ID: 929 5757 3013
Password: 359444

To return to the LIVE educational program 10:40am, click here.